

# Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GDBBE481C2B2EN.html>

Date: August 2024

Pages: 127

Price: US\$ 3,200.00 (Single User License)

ID: GDBBE481C2B2EN

## Abstracts

### Report Overview

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.

This report provides a deep insight into the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

market in any manner.

## Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

### Key Company

Pfizer Inc

GlaxoSmithKline Plc

Eidos Therapeutics

Ionis Pharmaceuticals, Inc

Alnylam Pharmaceuticals

Prothena Corporation Plc

Intellia Therapeutics, Inc

Corino Therapeutics, Inc

Market Segmentation (by Type)

Transthyretin Stabilizers

Nonsteroidal Anti-inflammatory Drugs (NSAID)

RNAi Therapy

Others

## Market Segmentation (by Application)

Hereditary Transthyretin Amyloidosis (hATTR)

Wild Type Transthyretin Amyloidosis (wtATTR)

## Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

## Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market

## Overview of the regional outlook of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market:

### Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

### Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

### Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types,

covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

## Contents

### **1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE**

1.1 Market Definition and Statistical Scope of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

1.2 Key Market Segments

1.2.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Type

1.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

### **2 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET OVERVIEW**

2.1 Global Market Overview

2.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

### **3 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET COMPETITIVE LANDSCAPE**

3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Manufacturers (2019-2024)

3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Manufacturers (2019-2024)

3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Sites, Area Served, Product Type

3.6 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Competitive Situation and Trends

3.6.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Rate

3.6.2 Global 5 and 10 Largest Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

## **4 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT INDUSTRY CHAIN ANALYSIS**

4.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

## **5 THE DEVELOPMENT AND DYNAMICS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET**

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

## **6 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY TYPE**

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2019-2024)



6.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Market Share by Type (2019-2024)

6.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price by Type (2019-2024)

## **7 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY APPLICATION**

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Sales by Application (2019-2024)

7.3 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Application (2019-2024)

7.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2019-2024)

## **8 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET SEGMENTATION BY REGION**

8.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region

8.1.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region

8.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region

8.2 North America

8.2.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

## 8.4 Asia Pacific

8.4.1 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

## 8.5 South America

8.5.1 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

## 8.6 Middle East and Africa

8.6.1 Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

## 9 KEY COMPANIES PROFILE

### 9.1 Pfizer Inc

9.1.1 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

9.1.2 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview

9.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Market Performance

9.1.4 Pfizer Inc Business Overview

9.1.5 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment SWOT Analysis

9.1.6 Pfizer Inc Recent Developments

### 9.2 GlaxoSmithKline Plc

9.2.1 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

- 9.2.2 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview
- 9.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Market Performance
- 9.2.4 GlaxoSmithKline Plc Business Overview
- 9.2.5 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment SWOT Analysis
- 9.2.6 GlaxoSmithKline Plc Recent Developments
- 9.3 Eidos Therapeutics
  - 9.3.1 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information
  - 9.3.2 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview
  - 9.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Market Performance
  - 9.3.4 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment SWOT Analysis
  - 9.3.5 Eidos Therapeutics Business Overview
  - 9.3.6 Eidos Therapeutics Recent Developments
- 9.4 Ionis Pharmaceuticals, Inc
  - 9.4.1 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information
  - 9.4.2 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview
  - 9.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Market Performance
  - 9.4.4 Ionis Pharmaceuticals, Inc Business Overview
  - 9.4.5 Ionis Pharmaceuticals, Inc Recent Developments
- 9.5 Alnylam Pharmaceuticals
  - 9.5.1 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information
  - 9.5.2 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview
  - 9.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Market Performance
  - 9.5.4 Alnylam Pharmaceuticals Business Overview
  - 9.5.5 Alnylam Pharmaceuticals Recent Developments
- 9.6 Prothena Corporation Plc
  - 9.6.1 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Basic Information

9.6.2 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Overview

9.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Market Performance

9.6.4 Prothena Corporation Plc Business Overview

9.6.5 Prothena Corporation Plc Recent Developments

#### 9.7 Intellia Therapeutics, Inc

9.7.1 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Basic Information

9.7.2 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Overview

9.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Market Performance

9.7.4 Intellia Therapeutics, Inc Business Overview

9.7.5 Intellia Therapeutics, Inc Recent Developments

#### 9.8 Corino Therapeutics, Inc

9.8.1 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Basic Information

9.8.2 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Overview

9.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)

#### Treatment Product Market Performance

9.8.4 Corino Therapeutics, Inc Business Overview

9.8.5 Corino Therapeutics, Inc Recent Developments

## **10 TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) TREATMENT MARKET FORECAST BY REGION**

10.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast

10.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country

10.2.3 Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region

10.2.4 South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

## Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Country

## **11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)**

11.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2025-2030)

11.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2025-2030)

11.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Forecast by Application (2025-2030)

11.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application

11.2.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) Forecast by Application (2025-2030)

## **12 CONCLUSION AND KEY FINDINGS**

## List Of Tables

### LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Comparison by Region (M USD)

Table 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2022)

Table 10. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Sites and Area Served

Table 12. Manufacturers Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Type

Table 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges

Table 22. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Type (K Units)



- Table 23. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (M USD)
- Table 24. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Type (2019-2024)
- Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Type (2019-2024)
- Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) by Type (2019-2024)
- Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Share by Type (2019-2024)
- Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price (USD/Unit) by Type (2019-2024)
- Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) by Application
- Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application
- Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Application (2019-2024) & (K Units)
- Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2019-2024)
- Table 33. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Application (2019-2024) & (M USD)
- Table 34. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2019-2024)
- Table 35. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2019-2024)
- Table 36. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2019-2024) & (K Units)
- Table 37. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2019-2024)
- Table 38. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2019-2024) & (K Units)
- Table 39. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2019-2024) & (K Units)
- Table 40. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Region (2019-2024) & (K Units)
- Table 41. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales by Country (2019-2024) & (K Units)
- Table 42. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM)

Treatment Sales by Region (2019-2024) & (K Units)

Table 43. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

Table 44. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview

Table 45. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. Pfizer Inc Business Overview

Table 47. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment SWOT Analysis

Table 48. Pfizer Inc Recent Developments

Table 49. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

Table 50. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview

Table 51. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. GlaxoSmithKline Plc Business Overview

Table 53. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment SWOT Analysis

Table 54. GlaxoSmithKline Plc Recent Developments

Table 55. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

Table 56. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview

Table 57. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment SWOT Analysis

Table 59. Eidos Therapeutics Business Overview

Table 60. Eidos Therapeutics Recent Developments

Table 61. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Basic Information

Table 62. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Overview

Table 63. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin



(2019-2024)

Table 64. Ionis Pharmaceuticals, Inc Business Overview

Table 65. Ionis Pharmaceuticals, Inc Recent Developments

Table 66. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information

Table 67. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview

Table 68. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin  
(2019-2024)

Table 69. Alnylam Pharmaceuticals Business Overview

Table 70. Alnylam Pharmaceuticals Recent Developments

Table 71. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information

Table 72. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview

Table 73. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin  
(2019-2024)

Table 74. Prothena Corporation Plc Business Overview

Table 75. Prothena Corporation Plc Recent Developments

Table 76. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information

Table 77. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview

Table 78. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin  
(2019-2024)

Table 79. Intellia Therapeutics, Inc Business Overview

Table 80. Intellia Therapeutics, Inc Recent Developments

Table 81. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Basic Information

Table 82. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Product Overview

Table 83. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM)  
Treatment Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin  
(2019-2024)

Table 84. Corino Therapeutics, Inc Business Overview

Table 85. Corino Therapeutics, Inc Recent Developments

Table 86. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2025-2030) & (K Units)

Table 87. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2025-2030) & (M USD)

Table 88. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 89. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 90. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 91. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 92. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Region (2025-2030) & (K Units)

Table 93. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Region (2025-2030) & (M USD)

Table 94. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Country (2025-2030) & (K Units)

Table 95. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 96. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Consumption Forecast by Country (2025-2030) & (Units)

Table 97. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Country (2025-2030) & (M USD)

Table 98. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Type (2025-2030) & (K Units)

Table 99. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Type (2025-2030) & (M USD)

Table 100. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Price Forecast by Type (2025-2030) & (USD/Unit)

Table 101. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) Forecast by Application (2025-2030)

Table 102. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Application (2025-2030) & (M USD)

## List Of Figures

### LIST OF FIGURES

- Figure 1. Product Picture of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD), 2019-2030
- Figure 5. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (M USD) (2019-2030)
- Figure 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (M USD)
- Figure 11. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Share by Manufacturers in 2023
- Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Share by Manufacturers in 2023
- Figure 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type
- Figure 18. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2019-2024)
- Figure 19. Sales Market Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type in 2023
- Figure 20. Market Size Share of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment by Type (2019-2024)
- Figure 21. Market Size Market Share of Transthyretin amyloid cardiomyopathy (ATTR-

CM) Treatment by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application

Figure 24. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application (2019-2024)

Figure 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Application in 2023

Figure 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application (2019-2024)

Figure 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application in 2023

Figure 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Growth Rate by Application (2019-2024)

Figure 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region (2019-2024)

Figure 30. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2023

Figure 32. U.S. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2023

Figure 37. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales

and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2023

Figure 44. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)

Figure 50. South America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Country in 2023

Figure 51. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales and Growth Rate (2019-2024) & (K Units)



Figure 61. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Type (2025-2030)

Figure 65. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Sales Forecast by Application (2025-2030)

Figure 66. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GDBBE481C2B2EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDBBE481C2B2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

